# OnCo record checkpoint-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/checkpoint-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "checkpoint-therapeutics" ;
  schema:name "Checkpoint Therapeutics"@en ;
  schema:alternateName "Checkpoint Therapeutics, Inc."@en ;
  schema:description "Checkpoint Therapeutics developed cosibelimab, an anti-PD-L1 antibody approved by the FDA in December 2024 for advanced cutaneous squamous cell carcinoma, and was acquired by Sun Pharma in 2025."@en ;
  schema:url <https://onco.cc/companies/checkpoint-therapeutics/>, <https://www.checkpointtherapeutics.com/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.checkpointtherapeutics.com/>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications> ;
  onco:tag "fda-oce-applicant" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/cutaneous-scc/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:drugs <https://onco.cc/drugs/cosibelimab/> .